Key Points
- Director Elizabeth Kwo sold 4,010 KMTS shares for approximately $97,283, reducing her ownership by 22.12%; the sale covered tax withholding tied to vested equity awards.
- Kestra Medical Technologies reported a quarterly loss of $0.75 per share, missing estimates by $0.14, on revenue of $30.97 million. Analysts expect a full-year loss of approximately $2.45 per share.
- The stock traded near $25.51, while analysts maintained a consensus “Hold” rating and an average price target of $28.38; four analysts rate it Buy, two Hold, and one Sell.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) Director Elizabeth Kwo sold 4,010 shares of the firm's stock in a transaction on Monday, September 21st. The shares were sold at an average price of $24.26, for a total transaction of $97,282.60. Following the sale, the director owned 14,116 shares in the company, valued at $342,454.16. The trade was a 22.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Trading Down 2.2%
Shares of Kestra Medical Technologies stock opened at $25.51 on Thursday. The company has a market capitalization of $1.52 billion, a P/E ratio of -9.55 and a beta of 0.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. The company has a fifty day moving average of $25.13 and a 200 day moving average of $22.74. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). The business had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have weighed in on KMTS. Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a "market perform" rating for the company. BTIG Research restated a "buy" rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Piper Sandler reaffirmed an "overweight" rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, September 16th. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kestra Medical Technologies has a consensus rating of "Hold" and a consensus target price of $28.38.
Check Out Our Latest Stock Report on Kestra Medical Technologies
Hedge Funds Weigh In On Kestra Medical Technologies
Institutional investors and hedge funds have recently made changes to their positions in the business. Corient Private Wealth LP raised its position in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. California State Teachers Retirement System increased its stake in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after acquiring an additional 7,844 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock valued at $1,844,000 after purchasing an additional 5,731 shares during the period. Quantinno Capital Management LP purchased a new stake in Kestra Medical Technologies during the first quarter valued at approximately $431,000. Finally, Sei Investments Co. lifted its stake in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company's stock valued at $4,726,000 after purchasing an additional 43,753 shares during the last quarter.
Kestra Medical Technologies Company Profile
(
Get Free Report)
Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company's primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient's heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.
The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
